1/22
Vocabulary practice flashcards covering Multiple Sclerosis (MS) disease subtypes, disease-modifying therapy (DMT) drug classes, high-yield pharmacology facts, safety monitoring, and relapse management.
Multiple Sclerosis (MS)
chronic, immune-mediated disease of the CNS characterized by inflammation, demyelination, and neuroaxonal injury.
Clinically Isolated Syndrome (CIS)
first neurologic episode suggestive of inflammatory demyelination.
Relapsing-Remitting MS (RRMS)
MS subtype characterized by relapses followed by partial or complete recovery.
Secondary Progressive MS (SPMS)
MS disease course characterized by gradual disability progression following an initial relapsing course; it may be categorized as active or nonactive.
Primary Progressive MS (PPMS)
MS disease subtype defined by disability progression continuous from disease onset.
Disease-Modifying Therapies (DMTs)
Agents that reduce inflammatory disease activity and, depending on the specific therapy and population, slow disability accumulation; they do not cure MS.
Interferon Beta
injectable DMT class associated with flu-like symptoms, depression concerns, and the need for CBC, LFT, and TSH monitoring.
Avonex
Rebif
Betaseron
Extavia
Plegridy
Glatiramer Acetate
A subcutaneous injection DMT associated with injection-site reactions and transient post-injection reactions.
Copaxone
Glatopa
Fumarates
An oral DMT class associated with flushing, GI effects, lymphopenia, and PML risk.
Tecfidera
Vumerity
Bafiertam
S1P Receptor Modulators
An oral DMT class associated with bradycardia, macular edema, infection risk, and rebound disease activity after discontinuation.
Gilenya
Mayzent
Zeposia
Ponvory
Anti-CD20 Monoclonal Antibodies
A DMT class that causes B-cell depletion and requires HBV screening, infection monitoring, and quantitative immunoglobulin monitoring.
Ocrevus
Kesimpta
Briumvi
ocrelizumab
Ocrevus
IV anti-CD20 monoclonal antibody administered every 6 months after initial split dosing; it is FDA-approved for relapsing forms of MS and primary progressive MS (PPMS).
ofatumumab
Kesimpta
at-home subcutaneous self-injection anti-CD20 therapy given as loading doses at weeks 0, 1, and 2, followed by monthly maintenance starting at week 4.
natalizumab
Tysabri
anti-α4 integrin monoclonal antibody given IV every 4 weeks that blocks leukocyte migration into the CNS; associated with progressive multifocal leukoencephalopathy (PML) and managed via TOUCH REMS.
siponimod
Mayzent
oral, once-daily S1P modulator used particularly in active SPMS that requires CYP2C9 genotyping prior to initiation (CYP2C9 3/3 genotype is contraindicated).
fingolimod
Gilenya
oral, once-daily S1P modulator requiring first-dose cardiac observation due to bradycardia and AV block risks; also associated with macular edema, infections, and severe rebound MS activity upon stopping.
teriflunomide
Aubagio
oral, once-daily pyrimidine synthesis inhibitor associated with hepatotoxicity and embryo-fetal toxicity, possessing a long elimination period that can be cleared via an accelerated elimination procedure.
Accelerated Elimination Procedure
A washout regimen using cholestyramine or activated charcoal to rapidly eliminate Aubagio (teriflunomide) from the body.
cladribine
Mavenclad
oral purine antimetabolite administered in short courses over two years (not continuously); requires lymphocyte monitoring and carries warnings for malignancy and embryo-fetal toxicity.
lemtuzumab
Lemtrada
anti-CD52 monoclonal antibody associated with autoimmune disorders (including autoimmune thyroid disease and ITP), infusion reactions, and prolonged monitoring.
Progressive Multifocal Leukoencephalopathy (PML)
A serious viral brain infection associated with natalizumab and fumarates; risk increases with anti-JCV antibody positivity, longer treatment duration, and prior immunosuppression.
Acute MS Relapse Management
Short-term treatment using high-dose corticosteroids (typically IV methylprednisolone or an equivalent high-dose oral regimen), or plasma exchange for severe steroid-refractory attacks, to accelerate clinical recovery.
Pseudo-relapse
A temporary worsening of preexisting neurologic symptoms triggered by infection, fever, or overheating, occurring without new inflammatory demyelinating disease activity.